One dose of protein-targeting CAR-T cells shrinks solid tumors in preclinical tests
CAR-T cell therapies have fundamentally transformed the treatment of several blood and lymph node cancers. However, their use in solid tumors such as liver, breast or lung cancer has so far been significantly more difficult. This is due, among other things, to the lack of suitable target structures on the cancer cells. Cancer immunotherapies typically target features that are characteristic of a…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Master protocol trials could reimagine the future of rare disease research
United Kingdom
-
Warm temperatures curb appetite but can still promote weight gain, animal experiments find
United Kingdom
-
New model predicts growth hormone therapy response in children with short stature
United Kingdom
-
HIV services plunge at four providers in Uganda and Zimbabwe after U.S. aid cuts
United Kingdom
-
Health services may be missing the link between alcohol problems and eating disorders, study suggests
United Kingdom
-
New workflow rapidly identifies deadly fungal bloodstream infections
United Kingdom
-
Virtual patients could help flag medical device risks missed by conventional studies
United Kingdom
-
Outside school hours care program helps kids be more active and stay off screens
United Kingdom